Literature DB >> 23303498

Molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa isolates in a pediatric population of patients with cystic fibrosis and determination of risk factors for infection with the Houston-1 strain.

Ruth Ann Luna1, Laura A Millecker, C Renee Webb, Sally K Mason, Elaine M Whaley, Jeffrey R Starke, Peter W Hiatt, James Versalovic.   

Abstract

Multiyear molecular epidemiological surveillance of multidrug-resistant Pseudomonas aeruginosa (MRPA) in a pediatric cystic fibrosis care center identified an endemic MRPA strain (Houston-1). Recent hospitalization was found to be a statistically significant risk factor for acquisition of the endemic strain. Multiple infection control improvements led to the reduced incidence of the Houston-1 strain in the CF population.

Entities:  

Mesh：

Year:  2013        PMID： 23303498      PMCID： PMC3666811          DOI： 10.1128/JCM.02157-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  18 in total

1.  Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic.

Authors:  A M Jones; J R Govan; C J Doherty; M E Dodd; B J Isalska; T N Stanbridge; A K Webb
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

2.  Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa.

Authors:  B J Lang; S D Aaron; W Ferris; P C Hebert; N E MacDonald
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

3.  Rapid genotyping of Pseudomonas aeruginosa isolates harboured by adult and paediatric patients with cystic fibrosis using repetitive-element-based PCR assays.

Authors:  Melanie W Syrmis; Mark R O'Carroll; Theo P Sloots; Chris Coulter; Claire E Wainwright; Scott C Bell; Michael D Nissen
Journal:  J Med Microbiol       Date:  2004-11       Impact factor: 2.472

4.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  G M Nixon; D S Armstrong; R Carzino; J B Carlin; A Olinsky; C F Robertson; K Grimwood
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

5.  Clonal strains of Pseudomonas aeruginosa in paediatric and adult cystic fibrosis units.

Authors:  M R O'Carroll; M W Syrmis; C E Wainwright; R M Greer; P Mitchell; C Coulter; T P Sloots; M D Nissen; S C Bell
Journal:  Eur Respir J       Date:  2004-07       Impact factor: 16.671

6.  Comparison of arbitrarily primed PCR and macrorestriction (pulsed-field gel electrophoresis) typing of Pseudomonas aeruginosa strains from cystic fibrosis patients.

Authors:  D Kersulyte; M J Struelens; A Deplano; D E Berg
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

Review 7.  Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.

Authors:  Lisa Saiman; Jane Siegel
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

8.  Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation.

Authors:  F P Edenborough; H R Stone; S J Kelly; P Zadik; C J Doherty; J R W Govan
Journal:  J Cyst Fibros       Date:  2004-03       Impact factor: 5.482

9.  Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.

Authors:  Fiona W Scott; Tyrone L Pitt
Journal:  J Med Microbiol       Date:  2004-07       Impact factor: 2.472

10.  Increased morbidity associated with chronic infection by an epidemic Pseudomonas aeruginosa strain in CF patients.

Authors:  M Al-Aloul; J Crawley; C Winstanley; C A Hart; M J Ledson; M J Walshaw
Journal:  Thorax       Date:  2004-04       Impact factor: 9.139
View more
  9 in total

1.  Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.

Authors:  Michael D Parkins; Bryan A Glezerson; Christopher D Sibley; Kristen A Sibley; Jessica Duong; Swathi Purighalla; Christopher H Mody; Matthew L Workentine; Douglas G Storey; Michael G Surette; Harvey R Rabin
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

2.  Antimicrobial Susceptibility of Pseudomonas aeruginosa Isolated from Cystic Fibrosis Patients in Northern Europe.

Authors:  Muhammad-Hariri Mustafa; Hussein Chalhoub; Olivier Denis; Ariane Deplano; Anne Vergison; Hector Rodriguez-Villalobos; Michael M Tunney; J Stuart Elborn; Barbara C Kahl; Hamidou Traore; Francis Vanderbist; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Incidence and prevalence of common respiratory pathogens before and after implementation of the Cystic Fibrosis Foundation Infection Prevention and Control Guideline.

Authors:  Christy Kim; Elizabeth delaRiva-Velasco; Arvind Budhram; Folashade Farri; Daniel Krich; Sheila S Nolan; Suzette Gjonaj; Lisa Paul; Allen J Dozor; John J Welter
Journal:  J Infect Prev       Date:  2019-09-25

4.  Multidrug resistant Pseudomonas aeruginosa survey in a stream receiving effluents from ineffective wastewater hospital plants.

Authors:  Mary Joyce Targino Lopes Magalhães; Gemilson Pontes; Paula Takita Serra; Antonio Balieiro; Diogo Castro; Fabio Alessandro Pieri; James Lee Crainey; Paulo Afonso Nogueira; Patricia Puccinelli Orlandi
Journal:  BMC Microbiol       Date:  2016-08-24       Impact factor: 3.605

5.  Cystic Fibrosis Patients Infected With Epidemic Pseudomonas aeruginosa Strains Have Unique Microbial Communities.

Authors:  Nicole Acosta; Barbara Waddell; Alya Heirali; Ranjani Somayaji; Michael G Surette; Matthew L Workentine; Harvey R Rabin; Michael D Parkins
Journal:  Front Cell Infect Microbiol       Date:  2020-04-24       Impact factor: 5.293

6.  Natural quorum sensing inhibitors effectively downregulate gene expression of Pseudomonas aeruginosa virulence factors.

Authors:  Syed A K S Ahmed; Michelle Rudden; Thomas J Smyth; James S G Dooley; Roger Marchant; Ibrahim M Banat
Journal:  Appl Microbiol Biotechnol       Date:  2019-03-09       Impact factor: 4.813

7.  Complete Genome Sequence of the Multidrug-Resistant Pseudomonas aeruginosa Endemic Houston-1 Strain, Isolated from a Pediatric Patient with Cystic Fibrosis and Assembled Using Oxford Nanopore and Illumina Sequencing.

Authors:  Jennifer K Spinler; Sabeen Raza; Jessica K Runge; Ruth Ann Luna
Journal:  Microbiol Resour Announc       Date:  2019-10-24

8.  Phenotypic and Genotypic Comparison of Epidemic and Non-Epidemic Strains of Pseudomonas aeruginosa from Individuals with Cystic Fibrosis.

Authors:  Jessica Duong; Sean C Booth; Nathan K McCartney; Harvey R Rabin; Michael D Parkins; Douglas G Storey
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

9.  Genotypic Diversity within a Single Pseudomonas aeruginosa Strain Commonly Shared by Australian Patients with Cystic Fibrosis.

Authors:  Anna Sze Tai; Scott Cameron Bell; Timothy James Kidd; Ella Trembizki; Cameron Buckley; Kay Annette Ramsay; Michael David; Claire Elizabeth Wainwright; Keith Grimwood; David Mark Whiley
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.